The combined contraceptive vaginal device (NuvaRing®): A comprehensive review

Abstract

Objectives The aim of this study is to review the development of NuvaRing® over the past decade to illustrate its use-effectiveness and acceptance as an alternative contraceptive option for women.

Methods The data were extracted from the literature using computerised MEDLINE system. NuvaRing® is a new combined hormonal contraceptive vaginal ring made of ethylene-vinyl-acetate copolymer, releasing 120 μg etonorgestrel and 15 μg ethinyloestradiol per day. This ring is inserted on any day from day 1 to day 5 of a menstrual cycle for 21 days, thereafter removed for 7 days ring-free period and discarded.

Results Complete inhibition of ovulation is observed during treatment with this device. Clinical exposure to NuvaRing® for 1786 women-years has resulted in 21 pregnancies, giving a Pearl Index of 1.18. Withdrawal bleeding (4.7–5.3 days) is regular (97–99% of cycles) with rare incidence of irregular bleeding (2.6–6.4%). The cycle control is good with the use of this combined contraceptive vaginal ring. NuvaRing® is well tolerated and accepted by women as compared to oral pill.

Conclusions NuvaRing® is an effective vaginal contraceptive option for women. However, further study is needed for monitoring its long-term effectiveness and impact on patient's quality of life since the NuvaRing^R is marketed in many countries.

• Hormonal contraceptive
• Pregnancy
• Withdrawal bleeding
• Inhibition of ovulation
• Etonorgestrel
• Polymer